Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00034924.xml
Download PDF
Nuklearmedizin 2018; 57(03): 69-73
DOI: 10.3413/Nukmed-2018030003
DOI: 10.3413/Nukmed-2018030003
Original Article – Pro-Contra
“Das PSMA-PET/CT soll bei allen Patienten mit biochemischem Progress nach radikaler Prostatektomie für eine frühe Tumordetektion eingesetzt werden.”
Pro und Contra[*] PSMA-PET/CT has to be performed in every patient with biochemical recurrence following radical prostatectomy for early tumor detectionFurther Information
Publication History
received:
23 February 2018
accepted:
23 April 2018
Publication Date:
05 June 2018 (online)
Zusammenfassung
Die Debatte stellt die bekannte Evidenz zur Frage der PSMA-PET/CT beim biochemischen Rezidiv des Prostatakarzinoms dar und wägt interdisziplinär ab, in welcher Situation welcher Patient zur Wahl der adäquaten Therapieoption bildgebende Diagnostik erforderlich macht. Dabei werden grundsätzliche Überlegungen zur Versorgung onkologischer Patienten mit einbezogen.
Summary
The debate refers the known evidence for PSMA-PET/CT in biochemical recurrence of prostate cancer and consider carefully interdisciplinary in which situation which patient needs imaging to choose the adequate therapeutic option. General aspects for the care of cancer patients are taken into consideration.
* Die Debatte wurde am 23.02.2018 auf dem 33. Deutschen Krebskongress in Berlin geführt.
-
Literatur
- 1 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Konsultationsfassung: Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 4.0. 2016 AWMF Registernummer: 043/022OL, http://leitlinienprogrammonkologie.de/Prostatakarzinom.58.0.html (Zugriff am: 10.04.2018).
- 2 Afshar-Oromieh A, Holland-Letz T, Giesel FL. et al. Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging 2017; 44: 1258-1268.
- 3 Afshar-Oromieh A, Zechmann CM, Malcher A. et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/ CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014; 41: 11-20.
- 4 Bailey J, Piert M. Performance of (68)Ga-PSMA PET/CT for Prostate Cancer Management at Initial Staging and Time of Biochemical Recurrence. Curr Urol Rep 2017; 18: 84.
- 5 Bartkowiak D, Thamm R, Bottke D. et al. Prostatespecific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival. Acta Oncol 2018; 57: 362-367.
- 6 Boorjian SA, Thompson RH, Tollefson MK. et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol 2011; 59: 893-899.
- 7 Bouman-Wammes EW, van Dodewaard-De Jong JM, Dahele M. et al. Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT. Clin Genitourin Cancer 2017; 15: e773-e782.
- 8 Budaus L, Leyh-Bannurah SR, Salomon G. et al. Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. Eur Urol 2016; 69: 393-396.
- 9 Calais J, Fendler WP, Eiber M. et al. Impact of (68)Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. J Nucl Med 2018; 59: 434-441.
- 10 Cantiello F, Gangemi V, Cascini GL. et al. Diagnostic Accuracy of (64)Copper Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging of Intermediate to High-risk Prostate Cancer: Our Preliminary Experience. Urology 2017; 106: 139-145.
- 11 Dietlein F, Kobe C, Neubauer S. et al. PSA-Stratified Performance of (18)F and (68)Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer. J Nucl Med 2017; 58: 947-952.
- 12 Eiber M, Fendler WP, Rowe SP. et al. Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. J Nucl Med 2017; 58: 67S-76S.
- 13 Eiber M, Herrmann K, Calais J. et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. J Nucl Med 2018; 59: 469-478.
- 14 Eiber M, Maurer T, Souvatzoglou M. et al. Evaluation of Hybrid (6)(8)Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med 2015; 56: 668-674.
- 15 Evans JD, Jethwa KR, Ost P. et al. Prostate cancerspecific PET radiotracers: A review on the clinical utility in recurrent disease. Pract Radiat Oncol 2018; 08: 28-39.
- 16 Fendler WP, Calais J, Allen-Auerbach M. et al. (68)Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study. J Nucl Med 2017; 58: 1617-1623.
- 17 Fendler WP, Eiber M, Beheshti M. et al. (68)Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging 2017; 44: 1014-1024.
- 18 Habl G, Sauter K, Schiller K. et al. (68) Ga-PSMAPET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment. Prostate 2017; 77: 920-927.
- 19 Heck MM, Retz M, D’Alessandria C. et al. Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer. J Urol 2016; 196: 382-391.
- 20 Heidenreich A, Moul JW, Shariat S. et al. Role of salvage lymph node dissection in prostate cancer. Curr Opin Urol 2016; 26: 581-589.
- 21 Hofman MS, Hicks RJ, Maurer T. et al. Prostatespecific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. Radiographics 2018; 38: 200-217.
- 22 Jochumsen MR, Gormsen LC, Nielsen GL. 68Ga-PSMA Avid Primary Adenocarcinoma of the Lung With Complementary Low 18F-FDG Uptake. Clin Nucl Med 2018; 43: 117-119.
- 23 Kratochwil C, Bruchertseifer F, Giesel FL. et al. 225Ac-PSMA-617 for PSMA-Targeted alpha-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer. J Nucl Med 2016; 57: 1941-1944.
- 24 Maurer T, Robu S, Schottelius M. et al. (99m)Technetium-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate Cancer. Eur Urol. 2018 doi:10.1016/j.eururo.2018.03.013
- 25 Maurer T, Weirich G, Schottelius M. et al. Prostatespecific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer. Eur Urol 2015; 68: 530-534.
- 26 Morigi JJ, Stricker PD, van Leeuwen PJ. et al. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. J Nucl Med 2015; 56: 1185-1190.
- 27 Nair R, Lamb BW, Geurts N. et al. The Role of Local Therapy for Oligometastatic Prostate Cancer: Should We Expect a Cure?. Urol Clin North Am 2017; 44: 623-633.
- 28 Obek C, Doganca T, Demirci E. et al. The accuracy of (68)Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer. Eur J Nucl Med Mol Imaging 2017; 44: 1806-1812.
- 29 Osman MM, Iravani A, Hicks RJ. et al. Detection of Synchronous Primary Malignancies with (68)Ga-Labeled Prostate-Specific Membrane Antigen PET/CT in Patients with Prostate Cancer: Frequency in 764 Patients. J Nucl Med 2017; 58: 1938-1942.
- 30 Ost P, Reynders D, Decaestecker K. et al. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol 2018; 36: 446-453.
- 31 Perera M, Papa N, Christidis D. et al. Sensitivity, Specificity, and Predictors of Positive (68)Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016; 70: 926-937.
- 32 Pyka T, Weirich G, Einspieler I. et al. 68Ga-PSMAHBED-CC PET for Differential Diagnosis of Suggestive Lung Lesions in Patients with Prostate Cancer. J Nucl Med 2016; 57: 367-371.
- 33 Rahbar K, Ahmadzadehfar H, Kratochwil C. et al. German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. J Nucl Med 2017; 58: 85-90.
- 34 Rauscher I, Duwel C, Haller B. et al. Efficacy, Predictive Factors, and Prediction Nomograms for (68)Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/ Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. Eur Urol. 2018 doi:10.1016/j.eururo.2018.01.006.
- 35 Rigatti P, Suardi N, Briganti A. et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. Eur Urol 2011; 60: 935-943.
- 36 Roach PJ, Francis R, Emmett L. et al. The Impact of (68)Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. J Nucl Med 2018; 59: 82-88.
- 37 Salas RAFragomeni, Amir T, Sheikhbahaei S. et al. Imaging of Non-Prostate Cancers Using PSMATargeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms. J Nucl Med. 2018 doi:10.2967/jnumed.117.203570.
- 38 Schmidt-Hegemann NS, Fendler WP, Buchner A. et al. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy. Radiat Oncol 2017; 12: 176.
- 39 Sheikhbahaei S, Afshar-Oromieh A, Eiber M. et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur J Nucl Med Mol Imaging 2017; 44: 2117-2136.
- 40 Shetty D, Loh H, Bui C. et al. Elevated 68Ga Prostate-Specific Membrane Antigen Activity in Metastatic Non-Small Cell Lung Cancer. Clin Nucl Med 2016; 41: 414-416.
- 41 Shipley WU, Seiferheld W, Lukka HR. et al. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. N Engl J Med 2017; 376: 417-428.